Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 ...

Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

Therapies for kidney cancer have transformed treatment pathways, extending survival and improving outcomes; yet the role of the clinical nurse specialist (CNS) in uro-oncology remains undervalued and ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to ...

For the fifth consecutive year, Congress has adjourned and allowed Medicare cuts,” said Bruce A. Scott, MD, president of the AMA.

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...